Ideaya Biosciences price target lowered to $48 from $53 at RBC Capital
RBC Capital lowered the firm's price target on Ideaya Biosciences to $48 from $53 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P